Docetaxel in advanced gastric cancer

Anti-Cancer Drugs

Volumn 13, Issue 5, 2002, Pages 451-460

  Haller, Daniel G ^a   Misset, Jean Louis ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Advanced gastric cancer; Chemotherapy; Docetaxel

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DRUG DERIVATIVE; PACLITAXEL; TAXOID; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR;

ADENOCARCINOMA; CLINICAL TRIAL; HUMAN; METASTASIS; PATHOLOGY; REVIEW; STOMACH TUMOR; TREATMENT OUTCOME; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SURGERY; CROSS RESISTANCE; DRUG TOLERABILITY; HEMATOLOGIC DISEASE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS; HUMANS; PACLITAXEL; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME; HUMAN;

EID: 0035987084     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200206000-00003     Document Type: Review

References (46)

1. Medical management of advanced gastric cancer
2. Docetaxel delivers new management opportunities for gastrointestinal carcinomas
3. Estimates of the worldwide mortality from 25 cancers in 1990
4. Cancer statistics 1997
5. The role of epidemiology in understanding the health effects of Helicobacter pylori
6. Cancer epidemiology in the last century and the next decade
7. Achilles' heel of cancer
8. Mutations of p53 gene in gastric carcinoma in Taiwan
9. Early gastric cancer - Excellent prognosis after curative resection in 87 patients irrespective of submucosal infiltration, lymph-node metastases or tumour size
10. Characterization of early gastric cancer and proposal of the optimal therapeutic strategy
11. Chemotherapy of gastric cancer: A review
12. Surgical outcome of node-positive early gastric cancer with particular reference to nodal status
13. Adjuvant therapy after curative resection for gastric cancer: Metaanalysis of randomized trials
14. A systematic overview of chemotherapy effects in gastric cancer
15. Chemotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction
16. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery for locally advanced stomach cancer
17. Neoadjuvant chemotherapy for high-grade advanced gastric cancer
18. Chemotherapy for operable gastric cancer: Results of the Dutch randomized FAMTX group
19. Preoperative chemotherapy for stage III-IV gastric carcinoma: Feasibility, response and outcome after complete resection
20. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer
21. Studies in prognostic factors relating to chemotherapy for advanced gastric cancer
22. Efficacy of combined 5-fluorouracil and cisplatin in advanced gastric carcinomas. A phase II trial with prognostic factor analysis
23. The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer
24. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction
25. Advanced gastric cancer: Comparison of FAMTX (5-FU, adriamycin, methotrexate) versus ELF (etoposide, 5-FU, leucovorin) versus FUP (infusional 5-FU + cisplatin)
26. Controlled evaluation of three drug combination regimen versus fluorouracil alone for the therapy of advanced gastric cancer
27. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer
28. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer
29. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: A report for the Italian Group for the Study of Digestive Tract Cancer
30. The taxanes: An update
31. Evaluation of antitumour effects of docetaxel (Taxotere®) on human gastric cancers in vitro and in vivo
32. Mechanisms of Taxotere-related drug resistance in pancreatic carcinoma
33. Multidrug resistance phenotype and paclitaxel (Taxol) sensitivity in human renal carcinoma cell lines of different histologic types
34. Docetaxel (Taxotere™) in advanced gastric cancer: Results of a phase II clinical trial
35. Phase II trial of docetaxel (Taxotere®) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG)
36. A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: A cooperative study group trial (group B)
37. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: A Japanese Cooperative Study Group trial (group A)
38. 2 is active and well tolerated in patients with metastatic or recurrent gastric cancer
39. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): A phase II trial
40. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian cancer cells
41. Differential cytotoxic effects of docetaxel in a range of mammalian tumour cell lines and certain drug resistant sublines in vitro
42. Docetaxel and cisplatin combination therapy for advanced gastric cancer: Results of two phase II studies
43. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer
44. Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma
45. Multinational randomized phase II trial of docetaxel and cisplatin with or without 5-fluorouracil in patients with advanced gastric cancer or GE junction adenocarcinoma
46. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian Group for the Study of Digestive Tract Cancer